Marien Gesellschaft Siegen gGmbH
- Address
- Kampenstrasse 51, 57072 Siegen, Germany
Marien Gesellschaft Siegen gGmbH - Comprehensive Oncology and Hematology Research Center
Marien Gesellschaft Siegen gGmbH is a distinguished clinical research institution with specialized expertise in hematologic malignancies and gastrointestinal oncology. The center demonstrates particular strength in conducting advanced Phase III trials that evaluate novel therapeutic strategies, combination regimens, and personalized treatment approaches for complex cancer patients.
- Multiple myeloma research, including risk-adapted strategies, minimal residual disease assessment, and novel combination therapies with autologous stem cell transplantation
- Colorectal cancer trials investigating preoperative systemic therapy, post-resection chemotherapy, and adjuvant treatment guided by circulating tumor DNA biomarkers
- Lymphoma treatment optimization, focusing on reduced-toxicity regimens for advanced-stage Hodgkin lymphoma
- Hormone receptor-positive breast cancer studies evaluating personalized adjuvant therapy with CDK4/6 inhibitors
The center's research portfolio emphasizes precision oncology approaches, incorporating biomarker-driven patient selection and treatment stratification. Their involvement in multi-center trials demonstrates expertise in evaluating minimal residual disease monitoring, liquid biopsy technologies, and comparison of standard-of-care versus experimental therapeutic regimens. The center's comprehensive capabilities span across multiple cancer types, with a particular focus on optimizing treatment efficacy while minimizing treatment-related toxicity in both newly diagnosed and metastatic disease settings.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 27 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Marien Gesellschaft Siegen gGmbH
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Adjuvant Dynamic Marker-Adjusted Personalized Therapy: Ribociclib Plus Endocrine Therapy Versus Chemotherapy in HR+/HER2- Early Breast Cancer | WSG Westdeutsche Studiengruppe GmbH | Phase III | Not Recruiting | Jul 2019 | — |
IMP list
lock Showing 1 of 27 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 3 | Unknown | 2019-12-04 | 2025-04-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.